Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Apr 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new tool that uses artificial intelligence (AI) to help guide treatment for patients with triple negative breast cancer (TNBC). Researchers believe that measuring certain immune cells called Tumor-Infiltrating Lymphocytes (TILs) can help predict how well patients will respond to chemotherapy before surgery. The trial aims to see if this AI tool can accurately identify patients who are likely to have better outcomes, such as longer survival without cancer returning.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of non-metastatic triple negative breast cancer. You should also be planning to start treatment with chemotherapy. If you join, you will need to give consent for your tissue to be used in research. This trial is not yet recruiting participants, but it will welcome all genders. It’s a chance to be part of important research that could improve treatment options for TNBC in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Confirmed diagnosis of triple negative breast cancer (non-metastatic)
• • Planned for neo-adjuvant systemic therapy
• • Written consent to generic Tissue for Research donation
• Exclusion Criteria:
• • Patients declined consent for generic Tissue for Research donation